Projects
Research Partnerships
Our research partnerships are data-driven collaborations. Friends aggregates and analyzes data from partners conducting clinical trials, administering diagnostics, and providing routine patient care. These projects generate evidence and builds alignment to advance the use of innovative measures and approaches in oncology, driving policy change and improving patient outcomes.
HRD Harmonization Project, Digital PATH Project, ai.RECIST Project, TMB Harmonization Project
Diagnostic tests provide critical information to guide care for patients with cancer. Our diagnostics harmonization portfolio evaluates the capabilities and performance of diagnostic technologies to understand sources of variability and identify opportunities for improved alignment across platforms.
ctMoniTR Project, ai.RECIST Project
Early endpoints that are reasonably likely to predict long-term outcomes can help streamline clinical trials and accelerate the evaluation of new treatments. Our Early Endpoints Portfolio works to generate evidence supporting the use of early endpoints for regulatory decisions.
RWE Pilots 1.0 and 2.0, rw-Response, rwCare, External Control Arms
Real-world data (RWD) are routinely collected and have the potential to inform regulatory decision-making. Our Real-World Evidence portfolio develops and establishes methodology for using RWD to assess treatment outcomes.
Policy Initiatives
Our policy & regulatory initiatives bring together stakeholders to assess emerging challenges in oncology drug development and policy to help inform recommendations for modernizing regulatory frameworks and clinical trials.
Cell & Gene Therapies
Our cell and gene therapies (CGT) work focuses on enhancing the translation of evidence to support clinical development and adoption of these therapies.
Interim OS
Friends is addressing the challenges in interpreting interim OS data by bringing together experts from across the oncology community to develop frameworks and simulation-based approaches that enable careful design and comprehensive analysis of interim OS data.
Clinical Trial Eligibility Criteria
Friends partnered with the American Society of Clinical Oncology (ASCO) to develop recommendations for broadening overly restrictive eligibility criteria used in cancer clinical trials.
Lung-MAP
Friends is a founding member of Lung-MAP, a first-of-its kind public-private collaboration to reimagine and accelerate how investigational biomarker-defined therapies for lung cancer are tested and approved.
Tolerability & Dosing
Friends works to ensure oncology clinical trials incorporate patient-centered approaches to dosage optimization, generating evidence to inform regulatory decision-making and improve patient quality of life.
Friends Annual Meeting
Each November, The Friends Annual Meeting brings together stakeholders each November to explore emerging challenges in oncology drug development and propose innovative solutions to support continued progress.
Data Driven Insights & Analyses
Friends uses publicly available regulatory data to develop a series of interactive tools for exploring data and trends on oncology drug approvals. We hope these resources empower users to uncover their own insights and identify emerging trends.
Expedited Programs, Accelerated Approvals, Postmarketing Requirements and Commitments
Friends created interactive dashboards to gain data driven insights into the landscape of oncology drug development and FDA drug approvals.
About Breakthrough Therapies, Search Breakthrough Therapies
Friends worked with partners in all sectors to develop and implement the Breakthrough Therapy Designation (BTD). Today, we track drugs that have received the designation to provide a tool for assessing BTD’s impact.
Stay Updated
Subscribe to stay updated on groundbreaking developments in cancer research and policy.